Hims & Hers Health shares rose 5% Tuesday after announcing it will offer Eli Lilly’s Zepbound and Mounjaro through its weight loss platform, according to CNBC. Weight loss drugs have surged in popularity in recent years, and Hims & Hers added these to its weight loss program while navigating supply and regulatory challenges. A Lilly spokesperson said the company has no affiliation with Hims & Hers and noted that Zepbound may be cheaper for insured patients or those who buy directly.
2025